Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease

References

• Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34(1):125–134.
   PubMed Web of Science ®Google Scholar
• Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the third national health and nutrition examination survey (1988–1994). Arch Intern Med. 2002;162(12):1401–1408.
   PubMed Web of Science ®Google Scholar
• From https://www.usrds.org/2017/view/v2_02.aspx, Last visited on the 15th of February, 2018
   Google Scholar
• Wagner M, Alam A, Zimmermann J, et al. Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(7):1573–1579.
   PubMed Web of Science ®Google Scholar
• Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590.
   PubMed Web of Science ®Google Scholar
• Drüeke TB, Locatelli F, Clyne N, et al. CREATE investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–2084.
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. CHOIR investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–2098.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, et al. TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–2032.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoietin stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532–1542.
   PubMed Web of Science ®Google Scholar
• Available at: https://www.dopps.org/OurStudies/DOPPSPracticeMonitor.aspx Last viewed in the 18th of March, 2018
   Google Scholar
• Ma L, Zhao S. Risk factors for mortality in patients undergoing hemodialysis: a systematic review and meta-analysis. Int J Cardiol. 2017;238:151–158.
   PubMed Web of Science ®Google Scholar
• Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell. 2010;40(2):294–309. ••Review about mechanisms of response to hypoxic stress.
   PubMed Web of Science ®Google Scholar
• Semenza GL, Nejfelt MK, Chi SM, et al. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA. 1991;88:5680–5684.
   PubMed Web of Science ®Google Scholar
• Wang GL, Jiang B-H, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix–loop–helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92:5510–5514.
   PubMed Web of Science ®Google Scholar
• Mole DR, Blancher C, Copley RR, et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem. 2009;284(25):16767–16775.
   PubMed Web of Science ®Google Scholar
• Webb JD, Coleman ML, Pugh CW. Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci. 2009;66(22):3539–3554.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399–408. •A comprehensive review about the HIF system.
   PubMed Web of Science ®Google Scholar
• Kapitsinou PP, Liu Q, Unger TL, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood. 2010;116(16):3039–3048.
   PubMed Web of Science ®Google Scholar
• Scortegagna M, Ding K, Zhang Q, et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood. 2005;105(8):3133–3140.
   PubMed Web of Science ®Google Scholar
• Mastrogiannaki M, P M, Keith B, et al. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest. 2009;119(5):1159–1166.
   PubMed Web of Science ®Google Scholar
• Duan C. Hypoxia-inducible factor 3 biology: complexities and emerging themes. Am J Physiol Cell Physiol. 2016;310:C260–9. •A comprehensive review about the physiology of the HIF system.
   PubMed Web of Science ®Google Scholar
• Lisy K, Peet DJ. Turn me on: regulating HIF transcriptional activity. Cell Death Differ. 2008;15:642–649.
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–275.
   PubMed Web of Science ®Google Scholar
• Mahon PC, Hirota K, Semenza GLFIH-1. A novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001;15:2675–2686.
   PubMed Web of Science ®Google Scholar
• Kim SY, Yang EG. Recent advances in developing inhibitors for hypoxia-inducible factor prolyl hydroxylases and their therapeutic implications. Molecules. 2015;20(11):20551–20568.
   PubMed Web of Science ®Google Scholar
• Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294(5545):1337–1340.
   PubMed Web of Science ®Google Scholar
• Appelhoff RJ, Tian YM, Raval RR, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004;279(37):38458–38465.
   PubMed Web of Science ®Google Scholar
• Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107:43–54.
   PubMed Web of Science ®Google Scholar
• Metzen E, Berchner-Pfannschmidt U, Stengel P, et al. Intracellular localisation of human HIF-1α hydroxylases: implications for oxygen sensing. J Cell Sci. 2003;116(Pt 7):1319–1326.
   PubMed Web of Science ®Google Scholar
• Willam C, Maxwell PH, Nichols L, et al. HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol. 2006;41(1):68–77.
   PubMed Web of Science ®Google Scholar
• Takeda K, Cowan A, Fong G. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation. 2007;116:774–781.
   PubMed Web of Science ®Google Scholar
• Minamishima YA, Kaelin WG Jr. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science. 2010;329:407.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Gu J, Li L, et al. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell. 2009;16:413–424.
   PubMed Web of Science ®Google Scholar
• Oliver K, Taylor C, Cummins E. Hypoxia regulation of NF_B signalling during inflammation: the role of hydroxylases. Arthritis Ther. 2009;11:215.
   PubMed Web of Science ®Google Scholar
• Place TL, Domann FE. Prolyl-hydroxylase 3: evolving roles for an ancient signaling protein. Hypoxi. 2013;1:13–17.
   Google Scholar
• Tcholakov I, Grimshaw CE, Shi L, et al. Time-dependent inhibition of PHD2. Biosci Rep. 2017Jun 30;37(3):1–8.
   Web of Science ®Google Scholar
• Copeland RA. The drug-target residence time model: a 10-year retrospective. Nat Rev Drug Discov. 2016;15:87–94.
   PubMed Web of Science ®Google Scholar
• Yeh TL, Leissing TM, Abboud MI, et al. Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials. Chem Sci. 2017;8(11):7651–7668.
   PubMed Web of Science ®Google Scholar
• Shah YM, Matsubara T, Ito S, et al. Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab. 2009;9:152–164.
   PubMed Web of Science ®Google Scholar
• Taylor M, Qu A, Anderson ER, et al. Hypoxia-inducible factor 2α mediates the adaptive increased of intestinal ferroportin during iron deficiency in mice. Gastroenterology. 2011;140:2044–2055.
   PubMed Web of Science ®Google Scholar
• Rolfs A, Kvietikova I, Gassmann M, et al. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor 1. J Biol Chem. 1997;272:20055–20062.
   PubMed Web of Science ®Google Scholar
• Lok CN, Ponka P. Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem. 1999;274:24147–24152.
   PubMed Web of Science ®Google Scholar
• Liu YL, Ang SO, Weigent DA, et al. Regulation of ferrochelatase gene expression by hypoxia. Life Sci. 2004;75:2035–2043.
   PubMed Web of Science ®Google Scholar
• Gaweda AE. Markers of iron status in chronic kidney disease. Hemodial Int. 2017;21(Suppl 1):S21–S27.
   PubMed Web of Science ®Google Scholar
• Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110:1037–1044.
   PubMed Web of Science ®Google Scholar
• Mastrogiannaki M, Matak P, Mathieu JR, et al. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica. 2012;97:827–834.
   PubMed Web of Science ®Google Scholar
• Liu Q, Davidoff O, Niss K, et al. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest. 2012;122:4635–4644.
   PubMed Web of Science ®Google Scholar
• Schodel J, Oikonomopoulos S, Ragoussis J, et al. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood. 2011;117:e207–e217.
   PubMed Web of Science ®Google Scholar
• Taylor CT, Colgan SP. Regulation of immunity and inflammation by hypoxia in immunological niches. Nat Rev Immunol. 2017 Dec;17(12):774–785.
   PubMed Web of Science ®Google Scholar
• Provenzano R, Besarab A, Sun CH, et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol. 2016;11:982–991. •A randomized clinical trial in patients with non-dialysis CKD, who were treated with different doses and frequencies of roxadustat.
   PubMed Web of Science ®Google Scholar
• Ogoshi Y, Matsui T, Mitani I, et al. Discovery of JTZ-951: a HIF prolyl hydroxylase inhibitor for the treatment of renal anemia. ACS Med Chem Lett. 2017;8(12):1320–1325.
   PubMed Web of Science ®Google Scholar
• Haase VH, Chertow GM, Block GA, et al. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Nephrol Dial Transplant 2018; Apr 16. Epub ahead of print.
   PubMedGoogle Scholar
• Seeley TW. Novel and beneficial pharmacodynamic properties of endogenous EPO and ‘complete erythropoiesis’ induced by selective HIF prolyl hydroxylase inhibitors [abstract]. J Am Soc Nephrol. 2005;16:761A.
   Google Scholar
• Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30(10):1665–1673. •A phase II clinical study of roxadustat in non-dialysis CKD patients.
   PubMed Web of Science ®Google Scholar
• Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;67(6):912–924.
   PubMed Web of Science ®Google Scholar
• Chen N, Qian J, Chen J, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant. 2017;32(8):1373–1386.
   PubMed Web of Science ®Google Scholar
• Besarab A, Chernyavskaya E, Motylev I, et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol. 2016;27:1225–1233. •A phase II clinical study of roxadustat in dialysis patients randomised to different iron regimens.
   PubMed Web of Science ®Google Scholar
• Shalwitz R, Hartman R, Flinn C, et al. AKB-6548, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor reduces hepcidin and ferritin while it increases reticulocyte production and total iron binding capacity in healthy adults. J Am Soc Nephrol. 2011;22:435A(FR-OR186).
   Google Scholar
• Buch A, Maroni BJ, Hartman CS. Dose exposure relationship of vadadustat is independent of the level of renal function. J Am Soc Nephrol. 2015;26:#SA-PO537.
   Google Scholar
• Pergola PE, Spinowitz BS, Hartman CS, et al. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016;90(5):1115–1122.
   PubMed Web of Science ®Google Scholar
• Martin ER, Smith MT, Maroni BJ, et al. Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am J Nephrol. 2017;45(5):380–388.
   PubMed Web of Science ®Google Scholar
• Haase VH, Khawaja Z, Chan J, et al. Vadadustat maintains Hemoglobin (Hb) levels in dialysis-dependent chronic kidney disease (DD-CKD) patients independent of systemic inflammation or prior dose of erythropoiesis-stimulating agent (ESA). J Am Soc Nephrol. 2016;27:318A(abstract).
   Google Scholar
• Ariazi JL, Duffy KJ, Adams DF, et al. Discovery and preclinical characterization of gsk1278863 (daprodustat), a small molecule hypoxia inducible factor-prolyl hydroxylase inhibitor for anemia. J Pharmacol Exp Ther. 2017;363(3):336–347.
   PubMed Web of Science ®Google Scholar
• U.S. National Institutes of Health. HIF inhibitor. ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed Sep 18, 2017.
   Google Scholar
• Brigandi RA, Johnson B, Oei C, et al. PHI112844 Investigators. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (gsk1278863) for anemia in ckd: a 28-day, phase 2a randomized trial. Am J Kidney Dis. 2016;67:861–871. •A randomized clinical that demonstrated the efficacy of GSK1278863 in increasing EPO production and consequently reticulocytes and Hb levels in patients with CKD.
   PubMed Web of Science ®Google Scholar
• Holdstock L, Meadowcroft AM, Maier R, et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol. 2016;27(4):1234–1244.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Tsubakihara Y, Nangaku M, et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. Am J Nephrol. 2017;45(2):127–135.
   PubMed Web of Science ®Google Scholar
• Beck H, Jeske M, Thede K, et al. Discovery of molidustat (BAY 85-3934): a small-molecule oral hif-prolyl hydroxylase (HIF-PH) inhibitor for the treatment of renal anemia. Chem Med Chem 2018;13(10):988–1003.
   Google Scholar
• Flamme I, Oehme F, Ellinghaus P, et al. Mimicking hypoxia to treat anemia: HIF stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014;9:e111838.58.
   Web of Science ®Google Scholar
• Macdougall I, Akizawa T, Berns J, et al. Molidustat increases haemoglobin in erythropoiesis stimulating agents (esa)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) abstract. 53rd Congress ERA-EDTA - Vienna May 21st - 24th. 2016;So036.
   Google Scholar
• Available at: https://clinicaltrials.gov/ct2/results?cond=molidustat&term=&cntry=&state=&city=&dist= Last viewed on the 9th of March, 2018
   Google Scholar
• Coyne DW, Kapoian T, Suki W, et al. DRIVE study group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients’ response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol. 2007;18(3):975–984.
   PubMed Web of Science ®Google Scholar
• Souma T, Nezu M, Nakano D, et al. Erythropoietin synthesis in renal myofibroblasts is restored by activation of hypoxia signaling. J Am Soc Nephrol. 2016 Feb;27(2):428–438.
   PubMed Web of Science ®Google Scholar
• Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010;21(12):2151–2156.
   PubMed Web of Science ®Google Scholar
• Kang JG, Sung HJ, Amar MJ, et al. Low ambient oxygen prevents atherosclerosis. J Mol Med (Berl). 2016;94(3):277–286.
   PubMed Web of Science ®Google Scholar